Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase II Study of Metronomic Chemotherapy in Elderly Non-fit Patients (>65 Years) With Aggressive B-Cell Lymphomas
Authors not listed
Fondazione Italiana Linfomi - ETS · 2017
Abstract
This is a phase II study of metronomic chemotherapy in elderly non-fit patients (\>65 years) with aggressive B-Cell lymphomas
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-06 MST
Cite this
APA
Anonymous. (2017). A Phase II Study of Metronomic Chemotherapy in Elderly Non-fit Patients (>65 Years) With Aggressive B-Cell Lymphomas. <em>Fondazione Italiana Linfomi - ETS</em>. https://clinicaltrials.gov/study/NCT03161054
Vancouver
Anonymous. A Phase II Study of Metronomic Chemotherapy in Elderly Non-fit Patients (>65 Years) With Aggressive B-Cell Lymphomas. Fondazione Italiana Linfomi - ETS. 2017.
BibTeX
@misc{anon2017APhase,
title = {A Phase II Study of Metronomic Chemotherapy in Elderly Non-fit Patients (>65 Years) With Aggressive B-Cell Lymphomas},
author = {Anonymous},
journal = {Fondazione Italiana Linfomi - ETS},
year = {2017},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
UMN Pharma Inc. 2012
Open access · US-GOV
Phase III Study of ASP7374 -Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Elderly Subjects
University of Cologne 2021
Open access · US-GOV
Phase II Trial of TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Fondazione Italiana Linfomi - ETS 2015
Open access · US-GOV
GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma A Phase II Study of the Fondazione Italiana Linfomi (FIL)
Prof. Dr. Med. Laimonas Griskevicius 2011
Open access · US-GOV
Study of Rituximab in Addition to Glucocorticoid in Pretreated Elderly or Unfit Patients With Chronic B Lymphocytic Leukemia
Lymphoma Study Association 2003
Open access · US-GOV
Study of ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 59 Years With High Risk Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 2-3)
Fondazione Italiana Linfomi - ETS 2011
Open access · US-GOV